Search tips
Search criteria 


Logo of physrepLink to Publisher's site
Physiol Rep. 2013 October; 1(5): e00100.
Published online 2013 October 20. doi:  10.1002/phy2.100
PMCID: PMC3841036

Electroencephalographic and early communicative abnormalities in Brattleboro rats


Reductions in the levels of the neuropeptide vasopressin (VP) and its receptors have been associated with schizophrenia. VP is also critical for appropriate social behaviors in humans as well as rodents. One of the prominent symptoms of schizophrenia is asociality and these symptoms may develop prodromally. A reduction in event-related potential (ERP) peak amplitudes is an endophenotype of schizophrenia. In this study, we use the Brattleboro (BRAT) rat to assess the role of VP deficiency in vocal communication during early development and on auditory ERPs during adulthood. BRAT rats had similar vocal communication to wild-type littermate controls during postnatal days 2 and 5 but the time between vocalizations was increased and the power of the vocalizations was reduced beginning at postnatal day 9. During adulthood, BRAT rats had deficits in auditory ERPs including reduced N40 amplitude and reduced low and high gamma intertrial coherence. These results suggest that the role of VP on vocal communication is an age-dependent process. Additionally, the deficits in ERPs indicate an impairment of auditory information processing related to the reduction in VP. Therefore, manipulation of the VP system could provide a novel mechanism for treatment for negative symptoms of schizophrenia.

Keywords: Brattleboro, ERP, schizophrenia, USV, vasopressin


Auditory event-related potentials (ERPs) are measures of brain electrical activity that are time locked to an auditory stimulus. Schizophrenia patients have abnormal ERP responses to auditory stimuli, which have led to ERPs being proposed as a biomarker for schizophrenia (Luck et al. 2011; Gandal et al. 2012). For instance, previous clinical studies using EEG have shown elevated baseline gamma activity at both frontal and total (e.g., all combined) electrode sites in patients with schizophrenia (Hamm et al. 2012). In addition to the surface ERP and EEG recorded in humans, similar techniques may be used to record from specific intracranial regions in rodents. The resulting rodent ERP and EEG produce an analogous response to humans, allowing for a high degree of translatability (Amann et al. 2008; Luck et al. 2011). Consistent with the human condition, mouse models of schizophrenia have demonstrated increased baseline gamma activity prior to auditory stimuli when using low impedance differential electrodes across multiple brain regions (Ehrlichman et al. 2009; Gandal et al. 2012; Hamm et al. 2012; Saunders et al. 2012a,b). Additionally, schizophrenia patients have a reduction in the N100 peak amplitude of the ERP which is replicated as an N40 amplitude reduction in schizophrenia rodent models (Maxwell et al. 2004; Halene et al. 2009; Amann et al. 2008; Dias et al. 2011; Featherstone et al. 2012). Previous studies in humans have shown that vasopressin (VP) enhances ERP peaks during an oddball paradigm (Born et al. 1998). Additionally, a VP agonist (DDAVP) given to schizophrenia patients improves negative symptom profiles. However, others have also shown no effect on memory impairments (Blake et al. 1978; Jenkins et al. 1979; Hostetter et al. 1980; Sahgal et al. 1982; Stein et al. 1984; Brambilla et al. 1986, 1989). Gene association studies have indicated a link between the promoter region of the V1aR gene and prepulse inhibition, an endophenotype of schizophrenia (Levin et al. 2009). Moreover, there is a reduction in circulating and CNS VP in schizophrenia, but several studies show no change. (Linkowski et al. 1984; Gjerris et al. 1985; Sorensen et al. 1985; Kishimoto et al. 1989; Legros and Ansseau 1992; Legros et al. 1992; Krishnamurthy et al. 2012; Elman et al. 2003). Furthermore, apomorphine-induced stimulation of VP levels in blood is significantly blunted in schizophrenia patients (Legros et al. 1992). Based on these studies VP is likely to be at least partially involved in the pathophysiology of schizophrenia.

The neurodevelopmental pathophysiology of schizophrenia produces prodromal symptoms prior to the onset of disease (MacCabe et al. 2013; Oribe et al. 2013). In rats, maternal separation-induced ultrasonic vocalizations (USVs) may be akin to ‘distress’ vocalizations or crying in human infants (Zeskind et al. 2011). These distress vocalizations provide a unique biologically and socially relevant signal essential for early survival and development (Zeskind et al. 2011). Similarly, previous studies in mice and rats have used maternal separation-induced USVs as an early developmental measure of disease (Hodgson et al. 2008; Scattoni et al. 2009; Bowers et al. 2013; Brudzynski 2013). For example, Foxp2 has previously been shown to mediate sex differences in Fibroblast growth factor 17 KO mice, a putative model for schizophrenia has impaired social behavior as well as decreased maternal separation-induced USVs (Scearce-Levie et al. 2008). Moreover, VP plays a role in maternal separation-induced USVs. For instance, systemic administration of the V1b antagonist SSR149415 reduces maternal separation-induced vocalizations in rat pups (Iijima and Chaki 2005). In contrast, central VP administration also reduced maternal separation-induced USVs (Winslow and Insel 1993). Interestingly, VP administered with a V1a antagonist had no effect on USVs, whereas VP administered with a V2 antagonist produced a reduction in USVs suggesting a role of V1a receptors in mediating USVs (Winslow and Insel 1993). Furthermore, the V1a/V2 antagonist JNJ-17308616 reduces maternal separation-induced USVs in rats as well (Bleickardt et al. 2009). Since increased and decreased VP signaling can mediate reductions in USVs, there is likely an optimal range and straying too far from this range results in impaired social behavior.

The Brattleboro (BRAT) rat carries a naturally occurring mutation of the Long-Evans rat with a single base deletion in exon 2 of the arginine vasopressin gene. This mutation results in an altered VP protein precursor and, as a result, no active VP production. The lack of VP in BRAT rat leads to a number of phenotypes including a decrease in dopamine levels in the frontal cortex as well as upregulation of striatal dopamine-2 receptors (Shilling et al. 2006; Cilia et al. 2010). Furthermore, adult BRAT rats demonstrate many behavioral deficits consistent with schizophrenia, such as increased startle, impaired cognitive performance, and reduced social function with mixed results regarding hyperactivity and anxiety phenotypes. (Brito et al. 1981; Gash et al. 1982; Warren and Gash 1983; Williams et al. 1983; Burnard et al. 1985; Herman et al. 1986; Stoehr et al. 1993; Engelmann and Landgraf 1994; Ingram et al. 1998; Jentsch et al. 2003; Aarde and Jentsch 2006; Shilling et al. 2006; Mlynarik et al. 2007; Frank and Landgraf 2008; Feifel et al. 2009, 2011; Schank 2009; Zelena et al. 2009; Cilia et al. 2010). Interestingly, at postnatal days 7 and 10, BRAT rats are hyperactive and have social deficits, consistent with both prodromal symptoms in schizophrenia as well as early developmental abnormalities in autism spectrum disorders (Schank 2009).

In this study, we assess the extent to which BRAT rats display deficits in the vocal communicative domain. Additionally, we determined the effect of reduced VP on auditory ERPs, as this measure shows distinct profiles in schizophrenia (Turetsky et al. 2009, 2007; Gandal et al. 2010).

Experimental Procedures


BRAT rats were bred at the University of Pennsylvania from two heterozygous breeding pairs (RrrcHsdBlu:BRAT-Avp+/di) purchased from the Rat Resource & Research Center (RRRC, Columbia, MO). All subsequent rats were bred from heterozygous pairs in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility and housed two to three per cage after weaning in a light- and temperature-controlled room. Animals used for EEG experiments were single housed after electrode implantation. 2House lights were on between 6 am and 6 pm and water and standard rodent chow were available ad libitum. Ultrasonic vocalization studies and ERP were conducted in separate cohorts of male homozygous knockout Brattleboro (BRAT) rats (Avpdi/di) and their littermate wild-type (WT) controls (Avp+/+) at the University of Pennsylvania during the light phase between 9:00 am and 5:00 pm. Due to the water retention impairments associated with the BRAT rats, cages were changed on a daily basis. Genotypes were determined by sequencing DNA extracted from tail snips for the Avp gene according to protocol provided by the RRRC (RRRC). All protocols were performed in accordance with University Laboratory Animal Resources guidelines and were approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania (Protocol #804371).

Ultrasonic vocalizations

Maternal separation-induced ultrasonic vocalizations

Male WT and BRAT rat pups from the same litters were assessed for maternal separation-induced distress ultrasonic vocalizations (USVs) on postnatal days 2, 5, 9, and 12 (WT n = 14, BRAT n = 9). Pups were removed from their home cage and placed in an empty plastic container 7″(W) × 11″ (D) × 5″ (H) with ambient air temperature maintained between 21 and 22°C. The chamber was cleaned between animals using 70% ethanol and allowed to air dry prior to testing further pups. Vocalizations were recorded for 120 sec using an ultrasonic range detector placed 10 cm above the plastic container (Pettersson Electronik D940 Ultrasound Detector, Uppsala, Sweden). Vocalizations were recorded for 120 sec to minimize stress caused by maternal separation. The microphone was placed 10 cm above the pup and was interfaced with a Micro1401 data acquisition unit (CED) sampling at 200 kHz recorded through Spike2 software (CED). Data were imported into Matlab for analysis. Sonograms were generated using a fast Fourier transform (FFT) of length 512 points using a Hanning window and infinite impulse response filtering between 25 and 55 kHz. The frequency range was chosen to capture all visible vocalizations on the sonogram of each individual rat pup for all age ranges tested. Vocalization frequency, interval, duration, and power were recorded using a variation of Matlab scripts available as freeware from the laboratory of Dr. Tim Holy (Holy and Guo 2005; Ise and Ohta 2009). Power was calculated using Fast Fourier Transform (FFT) of each call between 25 and 55 kHz and averaging the power of each call together as described (Holy and Guo 2005).

Social interaction-induced ultrasonic vocalizations

Two previously unexposed male rats of the same genotype (Pairs, WT n = 10, BRAT n = 8) were simultaneously placed into the middle of a 32″(W) × 18″ (D) × 12″(H) plastic chamber without bedding and video was recorded for 5 min in low light. Simultaneously, USVs were recorded in a similar fashion as with maternal separation-induced USVs with the exception that the microphone was 30 cm from the base of the chamber. The chamber was cleaned with 70% ethanol between recordings. The video was scored for the amount of time the animals spent socially interacting and vocalizations were manually counted. A social interaction was considered to be any time the snout of one animal was in direct contact with the other animal. All statistics were performed with Statistica software package (StatSoft, Inc., Tulsa, OK) using repeated measures ANOVA. Post hoc analyses were performed with Fisher LSD with a significance threshold of P = 0.05.

Event-related potentials

Electrode implantation

Rats between 300 and 400 g, (WT n = 11, BRAT n = 11) underwent stereotaxic implantation of two 3-channel electrodes (PlasticsOne Inc., Roanoke, VA) under isoflurane anesthesia. One electrode was placed in the prelimbic cortex (3.2 mm anterior, 1 mm lateral, and 4 mm ventral relative to bregma) and the other electrode was placed in the ipsilateral cerebellum which was used as a reference and ground (2 mm posterior, 2 mm lateral, and 2 mm ventral relative to lambda) in a similar fashion as that previously reported (Connolly et al. 2004, 2003; Maxwell et al. 2004; Ehrlichman et al. 2009). Since the recording and reference electrodes were located far apart from one another, activity recorded using this configuration extends far beyond the localized field generated within the prelimbic cortex, and, therefore reflects brain activity across a widespread area. Electrodes were placed in the prelimbic cortex because previous studies have shown prefrontal cortex impairments in schizophrenia (Edgar et al. 2012; Lisman 2012; Yoon et al. 2013). Histological verification of electrode placement was performed following the completion of experiments. Dental cement and ethyl cyanoacrylate (Elmers, Columbus, OH) were used to secure the electrode pedestal to the skull. Procedures were consistent with descriptions published elsewhere (Connolly et al. 2004, 2003; Siegel et al. 2005; Metzger et al. 2007).


After a minimum 1-week recovery time, ERPs were recorded during the presentation of an auditory task. Rats were transferred to a clean cage and cables were attached 20 min prior to recording. The auditory task consisted of a single click paradigm with presentation of a 9 kHz tone (10 ms, 85 dB) at a 4-sec interstimulus interval 200 times against 70 dB of background noise. EEG was recorded with a sampling rate of 1667 Hz and band-pass filtered between 1 and 500 Hz during collection. Stimuli were generated by Power 1401 hardware and Spike 6 software (Cambridge Electronic Design, Cambridge, UK) and were delivered through speakers attached to the cage top. All recordings were performed in a plastic cage 7″(W) × 11″ (D) × 5″ (H) with standard bedding, which was placed in a Faraday cage 15 min before stimulus onset.


For each animal, individual trials were rejected for movement artifact defined by two times the root mean square of the amplitude per rat. Average waves were created from 1000-ms prestimulus to 1000-ms poststimulus time. The N40 component was defined as the maximum negative deflection between 25 and 60 ms. Power analysis was performed using EEGLAB (Schwartz Center for Computational Neuroscience). Event-related low gamma (30–80 Hz and 0–60 ms) and high gamma (80–120 Hz and 0–60 ms) power were calculated using Morlet wavelets in 116 logarithmically spaced frequency bins between 4 and 120 Hz, with wavelet cycle numbers ranging from 2 to 10. All statistics were performed with Statistica software package using repeated measures ANOVA. Post hoc analyses were performed with Fisher LSD with a significance threshold of P = 0.05.


Social interaction

Adult BRAT rats spent less time interacting with each other than WT littermate controls in the freely interacting social interaction paradigm (Fig. (Fig.1,1, F1,16 = 6.79, P = 0.019). These deficits are consistent with prior reports and suggest that animals bred at the University of Pennsylvania share phenotypic deficits with those that have been previously described (Feifel et al. 2009).

Figure 1
Social interaction was assessed for 5 min between two freely interacting male adult rats of the same genotype. BRAT rats spent less time in direct contact with each other compared to littermate controls (*P < 0.05).

Ultrasonic vocalizations

USV recordings on days 2, 5, 9, and 12 after birth were analyzed for number of calls, intercall interval (time between calls), call power, and call duration. There was an overall increase in the number of calls through postnatal day 12 (Fig. (Fig.2A,2A, F3, 63 = 3.39, P = 0.023). Post hoc analysis indicated a trend in the BRAT rats toward a reduction in the number of calls (Fig. (Fig.2A,2A, F3, 63 = 2.38, P = 0.078). The intercall interval showed an overall increase among the BRAT rats (Fig. (Fig.2B,2B, F1, 19 = 11.18, P = 0.0035). Post hoc analysis indicated that the intercall interval was significantly longer in BRAT rats on postnatal days 9 and 12 (MS = 0.54, df = 74.61 P = 0.016 and P = 0.0097, respectively). Although both genotypes showed an increase in power over time (F3, 60 = 30.21, P < 0.0001), the call power was increased to a lesser extent in Brat rats when compared to littermate controls (Fig. (Fig.2C,2C, F1, 20 = 4.75, P = 0.041). Post hoc analysis showed that the power of the BRAT rats calls were specifically reduced on days 9 and 12 after birth (MS = 174E27, df = 72.61, P = 0.0091, P = 0.036). The duration of the calls was consistent across genotype and the testing days (Fig. (Fig.2D,2D, F3,60 = 0.95, P = 0.42). There was no difference among adult BRAT rats and their littermate controls for the number of USVs emitted during a social interaction (F1,10 = 0.36, P = 0.56, data not shown).

Figure 2
Maternal separation-induced distress ultrasonic vocalizations were measured in wild-type and BRAT rats during the first 12 days of life. USVs were analyzed for (A) number of calls, (B) intercall interval, (C) call power, and (D) call duration. There was ...


WT and BRAT rat EEG and ERP components were recorded and analyzed during an auditory task. No significant differences in ERP component latency (P20, N40, and P80) were observed between BRAT rats and WT littermate controls (Table (Table1).1). However, a significant reduction in N40 amplitude was observed among BRAT rats (Fig. (Fig.3A,B,3A,B, F1, 20 = 8.65, P = 0.008). Time spectrum analyses revealed a significant reduction in intertrial coherence (Fig. (Fig.4A,B,4A,B, ITC) for both low (0–60 s, 30–80 Hz) (Fig. (Fig.4C,4C, F1, 20 = 5.16, P = 0.034) and high (0–60 s 80–120 Hz) gamma (Fig. (Fig.4D,4D, F1, 20 = 9.39, P = 0.006), suggesting that cross-trial synchronization/consistency of gamma oscillations is disrupted by removal of VP.

Table 1
Latencies and amplitudes of ERP component peaks.
Figure 3
Event-related potential (ERP) profiles in wild-type and BRAT rats are shown. ERP components were extracted by averaging epochs resulting in (A) averaged ERP and (B) N40 amplitude. The BRAT rats have reductions in N40 amplitude (*P = 0.008).
Figure 4
Time frequency analysis of the EEG phase locked to the auditory stimulus illustrated as a heat map for (A) wild-type and (B) BRAT rats. The averaged phase-locked frequency components are depicted for (C) low gamma ITC, and (D) high gamma ITC. The BRAT ...


In this study, we report a reduction in neonatal USV during maternal separation as well as EEG oscillatory deficits in adult rats in BRAT rats that lack VP. The VP deficit-mediated reduction in auditory communication during early development (postnatal days 9 and 12) suggests that the effect of VP on social behavior is age dependent and emerges at time points corresponding to early postnatal period in humans (Zeskind et al. 2011). Previous data have shown that treatment with a V1b antagonist similarly causes reductions in maternal separation-induced vocalizations (Iijima and Chaki 2005). However, VP may also be interacting with other neurotransmitter systems. For example, the D1 agonist SKF81297 and the mGluR5 antagonist MPEP both produce similar reduction in maternal separation-induced vocalizations in rats (Iijima and Chaki 2005; Muller et al. 2009). In addition to the vocalization deficits, BRAT rats have abnormalities in locomotor activity and impairments in social behavior at postnatal days 7 and 10 (Schank 2009).

During adulthood, BRAT rats also have many behavioral deficits that are consistent with schizophrenia. Previous studies have shown that BRAT rats have deficits in prepulse inhibition of startle, social discrimination, and attentional engagement (Jentsch et al. 2003; Feifel et al. 2009, 2011). Additionally, we demonstrate that BRAT rats have reduced social interactions, consistent with previous studies and reduced social function in schizophrenia (Feifel et al. 2009). Interestingly, there were no quantitative deficits in the number of calls emitted among adult BRAT pairs during free social interaction. However, it is possible that adult BRAT rats may have subtle changes in the qualitative nature and types of calls rather than amount. Such changes could be informative regarding changes in prosody and inflection among people with schizophrenia (Jahshan et al. 2013). Therefore, future studies will assess such measures in BRAT rats. In addition to the behavioral deficits, we demonstrate a deficit in auditory ERPs similar to those seen in schizophrenia patients (Shin et al. 2010; Sharma et al. 2011; Swerdlow et al. 2012). BRAT rats have a reduction in low and high gamma intertrial coherence, indicating a reduction in the phase coherence and consistency of response to stimuli in the brain. Furthermore, previous studies conducted in mouse models have shown that NMDA hypofunction plays a critical role in the determination of ITC (Saunders et al. 2012a,b).

Pharmacological and parametric manipulations have suggested a close correspondence between the rodent N40 and human N100 (Metzger et al. 2007; Amann et al. 2008; Swerdlow et al. 2012). For example, pharmacological manipulations using dopamine agonists and nicotinic cholinergic agonists in rodents produce alterations in N40 that closely overlap with the effects such drugs have on the human N100 (Siegel et al. 2005; Maxwell et al. 2006; Kanes et al. 2007; Metzger et al. 2007; Amann et al. 2010; Halene and Siegel 2008; Rudnick et al. 2009, 2010; Cao et al. 2012; Featherstone et al. 2012). As such, it is likely that the reduction in N40 amplitude observed here in BRAT rats is analogous to the N100 reductions observed in schizophrenia patients. One potential explanation for the N40 deficit is an increase in the variability of the timing of the peak as opposed to a reduction in the amplitude of the peak (Jansen et al. 2010). In fact, variability of the time point at which the maximum deflection occurs between individual trials of the N100 peak may account for the reduction in average peak amplitude in schizophrenia patients (Jansen et al. 2010). There was no change in the N40 peak latency, an endophenotype typically associated with autism spectrum disorders (Gandal et al. 2010). Altogether, the EEG data suggest a VP-driven modulation of dopaminergic and glutaminergic tone in the BRAT rats.

The neonatal developmental deficits seen in BRAT rats are incongruous with the onset of prodromal deficits seen in many schizophrenia patients, which are primarily manifested during adolescence (Mees et al. 2011). It is possible to interpret these findings as more similar to autism spectrum disorders, which typically is diagnosed during infancy (Doyle and McDougle 2012). However, the BRAT rats exhibit deficits during adulthood such as the EEG deficits, which are not consistent with autism spectrum disorders. It remains unclear if the ERP deficits in BRAT rats develop during adolescence or are already present during early development but further studies are recommended to address this concern.


The role of VP in the etiology of schizophrenia remains unclear. One hypothesis posits that there is an increase in dopamine system function among BRAT rats. Previous data have shown decreased dopamine levels in the frontal cortex as well as upregulation of striatal dopamine-2 receptors in BRAT rats (Shilling et al. 2006; Cilia et al. 2010). The dopamine hypofunction in the frontal cortex accompanied by the dopamine hyperfunction in the striatum are consistent with the dopamine hypothesis for schizophrenia (Howes and Kapur 2009). Additionally, BRAT rats have reductions in PPI and elevations in startle response. These are all effects that are elicited by dopamine agonist administration (Talalaenko et al. 2006). However, the EEG deficits in ITC reported here cannot be explained with the dopamine hypothesis, suggest the involvement of another system or systems. Interestingly, VP also acts as a neurotransmitter in the amygdala and lateral septum; structures that are implicated in social and anxiety behaviors. Glutamate hypofunction can model the EEG deficits elicited in this study and social impairments previously reported. Therefore, it is conceivable that VP, acting as a neurotransmitter and neuromodulator, is able to model multiple endophenotypes of schizophrenia. Augmentation of the VP system may be useful as a novel therapeutic for schizophrenia. Consistent with this idea, a small study using a VP agonist as a treatment for negative symptoms and memory in schizophrenia demonstrated an improvement in negative symptoms and a trend toward improvement in memory (Brambilla et al. 1989). In conclusion, augmentation of the VP system may provide a novel treatment for the negative symptoms of schizophrenia and BRAT rats could provide valuable insight into the mechanisms in which these manipulations would have their effect.

Conflict of Interest

None declared.


  • Aarde SM, Jentsch JD. Haploinsufficiency of the arginine-vasopressin gene is associated with poor spatial working memory performance in rats. Horm. Behav. 2006;49:501–508. [PubMed]
  • Amann LC, Gandal MJ, Halene TB, Ehrlichman RS, White SL, McCarren HS, et al. Mouse behavioral endophenotypes for schizophrenia. Brain Res. Bull. 2010;83:147–161. [PubMed]
  • Amann LC, Phillips JM, Halene TB, Siegel SJ. Male and female mice differ for baseline and nicotine-induced event related potentials. Behav. Neurosci. 2008;122:982–990. [PubMed]
  • Blake DR, Dodd MJ, Evans JG. Vasopressin in amnesia. Lancet. 1978;1:608. [PubMed]
  • Bleickardt CJ, Mullins DE, Macsweeney CP, Werner BJ, Pond AJ, Guzzi MF, et al. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior. Psychopharmacology. 2009;202:711–718. [PubMed]
  • Born J, Pietrowsky R, Fehm HL. Neuropsychological effects of vasopressin in healthy humans. Prog. Brain Res. 1998;119:619–643. [PubMed]
  • Bowers JM, Perez-Pouchoulen M, Edwards NS, McCarthy MM. Foxp2 mediates sex differences in ultrasonic vocalization by rat pups and directs order of maternal retrieval. J. Neurosci. 2013;33:3276–3283. [PMC free article] [PubMed]
  • Brambilla F, Aguglia E, Massironi R, Maggioni M, Grillo W, Castiglioni R, et al. Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology. 1986;15:114–121. [PubMed]
  • Brambilla F, Bondiolotti GP, Maggioni M, Sciascia A, Grillo W, Sanna F, et al. Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobiology. 1989;20:113–119. [PubMed]
  • Brito GN, Thomas GJ, Gingold SI, Gash DM. Behavioral characteristics of vasopressin-deficient rats (Brattleboro strain) Brain Res. Bull. 1981;6:71–75. [PubMed]
  • Brudzynski SM. Ethotransmission: communication of emotional states through ultrasonic vocalization in rats. Curr. Opin. Neurobiol. 2013;23:310–317. [PubMed]
  • Burnard DM, Pittman QJ, Veale WL. Brattleboro rats display increased sensitivity to arginine vasopressin-induced motor disturbances. Brain Res. 1985;342:316–322. [PubMed]
  • Cao YA, Featherstone RE, Gandal MJ, Liang Y, Jutzeler C, Saunders J, et al. Nicotine normalizes event related potentials in COMT-Val-tg mice and increases gamma and theta spectral density. Behav. Neurosci. 2012;126:332–343. [PubMed]
  • Cilia J, Gartlon JE, Shilliam C, Dawson LA, Moore SH, Jones DN. Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. J Psychopharmacol. 2010;24:407–419. [PubMed]
  • Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, Tokarczyk J, et al. Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Res. 2003;992:85–95. [PubMed]
  • Connolly PM, Maxwell C, Liang Y, Kahn JB, Kanes SJ, Abel T, et al. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem. Res. 2004;29:1179–1188. [PubMed]
  • Dias EC, Butler PD, Hoptman MJ, Javitt DC. Early sensory contributions to contextual encoding deficits in schizophrenia. Arch. Gen. Psychiatry. 2011;68:654–664. [PubMed]
  • Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin. Neurosci. 2012;14:263–279. [PMC free article] [PubMed]
  • Edgar JC, Hunter MA, Huang M, Smith AK, Chen Y, Sadek J, et al. Temporal and frontal cortical thickness associations with M100 auditory activity and attention in healthy controls and individuals with schizophrenia. Schizophr. Res. 2012;140:250–257. [PMC free article] [PubMed]
  • Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, Contreras D, et al. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience. 2009;158:705–712. [PubMed]
  • Elman I, Lukas S, Shoaf SE, Rott D, Adler C, Breier A, et al. Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. J. Psychopharmacol. 2003;17:317–323. [PubMed]
  • Engelmann M, Landgraf R. Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol. Behav. 1994;55:145–149. [PubMed]
  • Featherstone RE, Phillips JM, Thieu T, Ehrlichman RS, Halene TB, Leiser SC, et al. Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials. PLoS ONE. 2012;7:e39775. [PMC free article] [PubMed]
  • Feifel D, Mexal S, Melendez G, Liu PY, Goldenberg JR, Shilling PD. The brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology. 2009;34:2011–2018. [PMC free article] [PubMed]
  • Feifel D, Shilling PD, Melendez G. Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy. J. Psychopharmacol. 2011;25:836–841. [PubMed]
  • Frank E, Landgraf R. The vasopressin system–from antidiuresis to psychopathology. Eur. J. Pharmacol. 2008;583:226–242. [PubMed]
  • Gandal MJ, Edgar JC, Ehrlichman RS, Mehta M, Roberts TP, Siegel SJ. Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biol. Psychiatry. 2010;68:1100–1106. [PubMed]
  • Gandal MJ, Anderson RL, Billingslea EN, Carlson GC, Roberts TP, Siegel SJ. Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia? Genes Brain Behav. 2012;11:740–750. [PMC free article] [PubMed]
  • Gash DM, Warren PH, Dick LB, Sladek JR, Jr, Ison JR. Behavioral modification in Brattleboro rats due to vasopressin administration and neural transplantation. Ann. N. Y. Acad. Sci. 1982;394:672–688. [PubMed]
  • Gjerris A, Hammer M, Vendsborg P, Christensen NJ, Rafaelsen OJ. Cerebrospinal fluid vasopressin–changes in depression. Br. J. Psychiatry. 1985;147:696–701. [PubMed]
  • Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL, et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav. 2009;8:661–675. [PMC free article] [PubMed]
  • Halene TB, Siegel SJ. Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle. J. Pharmacol. Exp. Ther. 2008;326:230–239. [PubMed]
  • Hamm JP, Ethridge LE, Shapiro JR, Stevens MC, Boutros NN, Summerfelt AT, et al. Spatiotemporal and frequency domain analysis of auditory paired stimuli processing in schizophrenia and bipolar disorder with psychosis. Psychophysiology. 2012;49:522–530. [PMC free article] [PubMed]
  • Herman JP, Thomas GJ, Laycock JF, Gartside IB, Gash DM. Behavioral variability within the Brattleboro and Long-Evans rat strains. Physiol. Behav. 1986;36:713–721. [PubMed]
  • Hodgson RA, Guthrie DH, Varty GB. Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: sensitivity to anxiolytic and antidepressant drugs. Pharmacol. Biochem. Behav. 2008;88:341–348. [PubMed]
  • Holy TE, Guo Z. Ultrasonic songs of male mice. PLoS Biol. 2005;3:e386. [PMC free article] [PubMed]
  • Hostetter G, Jubb SL, Kozlowski GP. An inability of subcutaneous vasopressin to affect passive avoidance behavior. Neuroendocrinology. 1980;30:174–177. [PubMed]
  • Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr. Bull. 2009;35:549–562. [PMC free article] [PubMed]
  • Iijima M, Chaki S. Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization. Pharmacol. Biochem. Behav. 2005;82:652–657. [PubMed]
  • Ingram CD, Ciobanu R, Coculescu IL, Tanasescu R, Coculescu M, Mihai R. Vasopressin neurotransmission and the control of circadian rhythms in the suprachiasmatic nucleus. Prog. Brain Res. 1998;119:351–364. [PubMed]
  • Ise S, Ohta H. Power spectrum analysis of ultrasonic vocalization elicited by maternal separation in rat pups. Brain Res. 2009;1283:58–64. [PubMed]
  • Jahshan C, Wynn JK, Green MF. Relationship between auditory processing and affective prosody in schizophrenia. Schizophr. Res. 2013;143:348–353. [PMC free article] [PubMed]
  • Jansen BH, Hu L, Boutros NN. Auditory evoked potential variability in healthy and schizophrenia subjects. Clin. Neurophysiol. 2010;121:1233–1239. [PMC free article] [PubMed]
  • Jenkins JS, Mather HM, Coughlan AK, Jenkins DG. Desmopressin in post-traumatic amnesia. Lancet. 1979;2:1245–1246. [PubMed]
  • Jentsch JD, Arguello PA, Anzivino LA. Null mutation of the arginine-vasopressin gene in rats slows attentional engagement and facilitates response accuracy in a lateralized reaction time task. Neuropsychopharmacology. 2003;28:1597–1605. [PubMed]
  • Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience. 2007;144:239–246. [PMC free article] [PubMed]
  • Kishimoto T, Hirai M, Ohsawa H, Terada M, Matsuoka I, Ikawa G. Manners of arginine vasopressin secretion in schizophrenic patients–with reference to the mechanism of water intoxication. Jpn. J. Psychiatry Neurol. 1989;43:161–169. [PubMed]
  • Krishnamurthy D, Harris LW, Levin Y, Koutroukides TA, Rahmoune H, Pietsch S, et al. Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J. Biol. Psychiatry. 2012;14:478–489. [PubMed]
  • Legros JJ, Gazzotti C, Carvelli T, Franchimont P, Timsit-Berthier M, von Frenckell R, et al. Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology. 1992;17:611–617. [PubMed]
  • Legros JJ, Ansseau M. Neurohypophyseal peptides and psychopathology. Prog. Brain Res. 1992;93:455–460. discussion 461. [PubMed]
  • Levin R, Heresco-Levy U, Bachner-Melman R, Israel S, Shalev I, Ebstein RP. Association between arginine vasopressin 1a receptor (AVPR1a) promoter region polymorphisms and prepulse inhibition. Psychoneuroendocrinology. 2009;34:901–908. [PubMed]
  • Linkowski P, Geenen V, Kerkhofs M, Mendlewicz J, Legros JJ. Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur. Arch. Psychiatry Neurol. Sci. 1984;234:162–165. [PubMed]
  • Lisman J. Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? Curr. Opin. Neurobiol. 2012;22:537–544. [PMC free article] [PubMed]
  • Luck SJ, Mathalon DH, O'Donnell BF, Hamalainen MS, Spencer KM, Javitt DC, et al. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol. Psychiatry. 2011;70:28–34. [PMC free article] [PubMed]
  • MacCabe JH, Wicks S, Lofving S, David AS, Berndtsson A, Gustafsson JE, et al. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. JAMA Psychiatry. 2013;70:261–270. [PubMed]
  • Maxwell CR, Kanes SJ, Abel T, Siegel SJ. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience. 2004;129:101–107. [PubMed]
  • Maxwell CR, Liang Y, Kelly MP, Kanes SJ, Abel T, Siegel SJ. Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. Neuroscience. 2006;141:1257–1264. [PMC free article] [PubMed]
  • Mees L, Zdanowicz N, Reynaert C, Jacques D. Adolescents and young adults at ultrahigh risk of psychosis: detection, prediction and treatment A review of current knowledge. Psychiatr Danub. 2011;23(Suppl 1):S118–S122. [PubMed]
  • Metzger KL, Maxwell CR, Liang Y, Siegel SJ. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol. Psychiatry. 2007;61:23–30. [PubMed]
  • Mlynarik M, Zelena D, Bagdy G, Makara GB, Jezova D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm. Behav. 2007;51:395–405. [PubMed]
  • Muller JM, Moore H, Myers MM, Shair HN. Dopamine's role in social modulation of infant isolation-induced vocalization: II. Maternally modulated infant separation responses are regulated by D1- and D2-family dopamine receptors. Dev. Psychobiol. 2009;51:158–172. [PMC free article] [PubMed]
  • Oribe N, Hirano Y, Kanba S, Del Re EC, Seidman LJ, Mesholam-Gately R, et al. Early and late stages of visual processing in individuals in prodromal state and first episode schizophrenia: an ERP study. Schizophr. Res. 2013;146:95–102. [PubMed]
  • Rudnick ND, Koehler C, Picciotto MR, Siegel SJ. Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials. Psychopharmacology. 2009;202:745–751. [PubMed]
  • Rudnick ND, Strasser AA, Phillips JM, Jepson C, Patterson F, Frey JM, et al. Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine Tob. Res. 2010;12:589–597. [PMC free article] [PubMed]
  • Sahgal A, Keith AB, Wright C, Edwardson JA. Failure of vasopressin to enhance memory in a passive avoidance task in rats. Neurosci. Lett. 1982;28:87–92. [PubMed]
  • Saunders JA, Gandal MJ, Roberts TP, Siegel SJ. NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders. Behav. Brain Res. 2012a;234:233–237. [PubMed]
  • Saunders JA, Gandal MJ, Siegel SJ. NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. Neurobiol. Dis. 2012b;46:93–100. [PubMed]
  • Scattoni ML, Crawley J, Ricceri L. Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Neurosci. Biobehav. Rev. 2009;33:508–515. [PMC free article] [PubMed]
  • Scearce-Levie K, Roberson ED, Gerstein H, Cholfin JA, Mandiyan VS, Shah NM, et al. Abnormal social behaviors in mice lacking Fgf17. Genes Brain Behav. 2008;7:344–354. [PubMed]
  • Schank JC. Early locomotor and social effects in vasopressin deficient neonatal rats. Behav. Brain Res. 2009;197:166–177. [PubMed]
  • Sharma A, Weisbrod M, Kaiser S, Markela-Lerenc J, Bender S. Deficits in fronto-posterior interactions point to inefficient resource allocation in schizophrenia. Acta Psychiatr. Scand. 2011;123:125–135. [PubMed]
  • Shilling PD, Kinkead B, Murray T, Melendez G, Nemeroff CB, Feifel D. Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol. Psychiatry. 2006;60:1278–1281. [PubMed]
  • Shin YW, Krishnan G, Hetrick WP, Brenner CA, Shekhar A, Malloy FW, et al. Increased temporal variability of auditory event-related potentials in schizophrenia and Schizotypal Personality Disorder. Schizophr. Res. 2010;124:110–118. [PMC free article] [PubMed]
  • Siegel SJ, Maxwell CR, Majumdar S, Trief DF, Lerman C, Gur RE, et al. Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience. 2005;133:729–738. [PubMed]
  • Sorensen PS, Gjerris A, Hammer M. Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J. Neurol. Neurosurg. Psychiatry. 1985;48:50–57. [PMC free article] [PubMed]
  • Stein D, Bannet J, Averbuch I, Landa L, Chazan S, Belmaker RH. Ineffectiveness of vasopressin in the treatment of memory impairment in chronic schizophrenia. Psychopharmacology. 1984;84:566–568. [PubMed]
  • Stoehr JD, Cheng SW, North WG. Homozygous Brattleboro rats display attenuated conditioned freezing responses. Neurosci. Lett. 1993;153:103–106. [PubMed]
  • Swerdlow NR, Light GA, Breier MR, Shoemaker JM, Saint Marie RL, Neary AC, et al. Sensory and sensorimotor gating deficits after neonatal ventral hippocampal lesions in rats. Dev. Neurosci. 2012;34:240–249. [PubMed]
  • Talalaenko AN, Krivobok GK, Pankrat'ev DV, Goncharenko NV. Neurochemical mechanisms of the dorsal pallidum in the antiaversive effects of anxiolytics in various models of anxiety. Neurosci. Behav. Physiol. 2006;36:749–754. [PubMed]
  • Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 2007;33:69–94. [PMC free article] [PubMed]
  • Turetsky BI, Bilker WB, Siegel SJ, Kohler CG, Gur RE. Profile of auditory information-processing deficits in schizophrenia. Psychiatry Res. 2009;165:27–37. [PMC free article] [PubMed]
  • Warren PH, Gash DM. Hyperreflexive behavior in Brattleboro rats. Peptides. 1983;4:421–424. [PubMed]
  • Williams AR, Carey RJ, Miller M. Effect of vasopressin on open field and activity behavior of the vasopressin-deficient (Brattleboro) rat. Peptides. 1983;4:717–720. [PubMed]
  • Winslow JT, Insel TR. Effects of central vasopressin administration to infant rats. Eur. J. Pharmacol. 1993;233:101–107. [PubMed]
  • Yoon JH, Minzenberg MJ, Raouf S, D'Esposito M, Carter CS. Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol. Psychiatry. 2013;74:122–129. [PMC free article] [PubMed]
  • Zelena D, Mergl Z, Makara GB. Postnatal development in vasopressin deficient Brattleboro rats with special attention to the hypothalamo-pituitary-adrenal axis function: the role of maternal genotype. Int. J. Dev. Neurosci. 2009;27:175–183. [PubMed]
  • Zeskind PS, McMurray MS, Garber KA, Neuspiel JM, Cox ET, Grewen KM, et al. Development of translational methods in spectral analysis of human infant crying and rat pup ultrasonic vocalizations for early neurobehavioral assessment. Front Psychiatry. 2011;2:56. [PMC free article] [PubMed]

Articles from Physiological Reports are provided here courtesy of Wiley-Blackwell